May 2026
1. WILLMANN J, Dee EC, Hendriks LEL, Dimitriou NM, et al
   Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
   J Clin Oncol. 2026 May 5:JCO2501958. doi: 10.1200/JCO-25-01958.
   

   >> Share

   
   April 2026
2. SHIMIZU T, Sands J, Yoh K, Spira A, et al
   Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
   J Clin Oncol. 2026 Apr 30:JCO2600937. doi: 10.1200/JCO-26-00937.
   

   >> Share

   
   
3. LI W, Zhang Y, Fan H, Yu Q, et al
   Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.
   J Clin Oncol. 2026 Apr 21:JCO2600434. doi: 10.1200/JCO-26-00434.
   

   >> Share

   
   
4. WALTER TP, Mazieres J, Otto J, Lena H, et al
   Nivolumab +/- Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
   J Clin Oncol. 2026;44:1120-1129.
   

   >> Share

   
   
5. PETERS S, Piha-Paul SA, Sehgal K, Calvo E, et al
   First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
   J Clin Oncol. 2026 Apr 20:JCO2502016. doi: 10.1200/JCO-25-02016.
   

   >> Share

   
   March 2026
6. BESSE B, Subbiah V, Curigliano G, Bowles DW, et al
   Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
   J Clin Oncol. 2026 Mar 26:JCO2501489. doi: 10.1200/JCO-25-01489.
   

   >> Share

   
   
7. SCHERPEREEL A, Baas P, Nowak AK, Tsao AS, et al
   Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
   J Clin Oncol. 2026;44:742-749.
   

   >> Share

   
   
8. ZHOU H, Zhao H, Hou X, Wang Y, et al
   Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.
   J Clin Oncol. 2026 Mar 4:JCO2501929. doi: 10.1200/JCO-25-01929.
   

   >> Share

   
   February 2026
9. ZHAO J, Graetz I, Howard D, Han X, et al
   Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non-Small Cell Lung Cancer.
   J Clin Oncol. 2026 Feb 13:JCO2501892. doi: 10.1200/JCO-25-01892.
   

   >> Share

   
   
10. REMON J, Cascone T, Peters S
    Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Feb 6:JCO2600221. doi: 10.1200/JCO-26-00221.
    

    >> Share

    
    
11. REUSS JE, Bazhenova L, Ismaila N, Abu Rous F, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502825. doi: 10.1200/JCO-25-02825.
    

    >> Share

    
    
12. PURI S, Leighl NB, Ismaila N, Rous FA, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.
    J Clin Oncol. 2026 Feb 3:JCO2502822. doi: 10.1200/JCO-25-02822.
    

    >> Share

    
    January 2026
13. WERMKE M, Gambardella V, Kuboki Y, Felip E, et al
    Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
    J Clin Oncol. 2026 Jan 22:JCO2502654. doi: 10.1200/JCO-25-02654.
    

    >> Share

    
    
14. CHEN Y, Liu L, Ming Y, Chen L, et al
    Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
    J Clin Oncol. 2026 Jan 22:JCO2501894. doi: 10.1200/JCO-25-01894.
    

    >> Share

    
    
15. REMON J, Cascone T, Peters S
    BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jan 22:JCO2502696. doi: 10.1200/JCO-25-02696.
    

    >> Share

    
    
16. RUSTHOVEN CG, Serizawa T, Yamamoto M
    Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials.
    J Clin Oncol. 2026 Jan 20:JCO2501794. doi: 10.1200/JCO-25-01794.
    

    >> Share

    
    
17. NOGUCHI M, Nimura K, Koide Y
    Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501867. doi: 10.1200/JCO-25-01867.
    

    >> Share

    
    
18. AKDOGAN O, Canaslan K, Hamitoglu B, Yazici O, et al
    Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases.
    J Clin Oncol. 2026 Jan 20:JCO2501729. doi: 10.1200/JCO-25-01729.
    

    >> Share

    
    
19. AIZER AA, Catalano PJ, Rahman R
    Reply to: "Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases," "Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,"
    J Clin Oncol. 2026 Jan 20:JCO2502528. doi: 10.1200/JCO-25-02528.
    

    >> Share

    
    
20. KEANE FK, Schoenfeld AJ
    Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer.
    J Clin Oncol. 2026 Jan 14:JCO2502726. doi: 10.1200/JCO-25-02726.
    

    >> Share

    
    
21. GOSS GD, Darling GE, Westeel V, Nakagawa K, et al
    Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jan 13:JCO2501828. doi: 10.1200/JCO-25-01828.
    

    >> Share

    
    
22. HIGGINS KA, Hu C, Ross HJ, Jabbour SK, et al
    Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
    J Clin Oncol. 2026 Jan 13:JCO2501569. doi: 10.1200/JCO-25-01569.
    

    >> Share

    
    
23. BRADLEY JD, Sugawara S, Lee KH, Ostoros G, et al
    Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
    J Clin Oncol. 2026 Jan 7:JCO2503012. doi: 10.1200/JCO-25-03012.
    

    >> Share

    
    December 2025
24. DIX DB, Khanna G, Renfro LA, Tfirn IC, et al
    Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533.
    J Clin Oncol. 2025;43:3822-3832.
    

    >> Share

    
    
25. PIOTROWSKA Z, Yu HA
    Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2502185. doi: 10.1200/JCO-25-02185.
    

    >> Share

    
    
26. YAO W, Zhou Q, Shi T, Xu L, et al
    Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2501501. doi: 10.1200/JCO-25-01501.
    

    >> Share

    
    
27. FELIP E, Wakelee HA, Fu C, Deng Y, et al
    Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
    J Clin Oncol. 2025 Dec 10:JCO2502102. doi: 10.1200/JCO-25-02102.
    

    >> Share

    
    
28. HE J, Zheng B, Wang Z
    Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity.
    J Clin Oncol. 2025 Dec 10:JCO2501540. doi: 10.1200/JCO-25-01540.
    

    >> Share

    
    
29. TOMASINI P, Wang Y, Li Y, Felip E, et al
    Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
    J Clin Oncol. 2025 Dec 1:JCO2402835. doi: 10.1200/JCO-24-02835.
    

    >> Share

    
    October 2025
30. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    

    >> Share

    
    
31. JOHNSON ML, Smit EF, Felip E, Ramalingam SS, et al
    Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Oct 19:101200JCO2502023. doi: 10.1200/JCO-25-02023.
    

    >> Share

    
    
32. RUDIN CM, Johnson ML, Paz-Ares L, Nishio M, et al
    Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial.
    J Clin Oncol. 2025 Oct 14:101200JCO2502142. doi: 10.1200/JCO-25-02142.
    

    >> Share

    
    
33. BRADLEY JD, Sugawara S, Lee KH, Ostoros G, et al
    Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
    J Clin Oncol. 2025 Oct 13:JCO2500036. doi: 10.1200/JCO-25-00036.
    

    >> Share

    
    
34. ZHANG Y, Qian B, Song Q, Ma J, et al
    Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.
    J Clin Oncol. 2025;43:3081-3089.
    

    >> Share

    
    September 2025
35. CHAUNZWA TL, Jabbour SK, Pike LRG, Cooper AJ, et al
    Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era.
    J Clin Oncol. 2025 Sep 26:JCO2501817. doi: 10.1200/JCO-25-01817.
    

    >> Share

    
    
36. YANG JC, Wang M, Doucet L, Fan Y, et al
    Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
    J Clin Oncol. 2025 Sep 9:JCO2500788. doi: 10.1200/JCO-25-00788.
    

    >> Share

    
    August 2025
37. WANG Z, Zhu X
    Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?
    J Clin Oncol. 2025 Aug 21:JCO2501055. doi: 10.1200/JCO-25-01055.
    

    >> Share

    
    
38. PEROL M, Li W, Lai RK, Zhou C, et al
    Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
    J Clin Oncol. 2025 Aug 21:JCO2501448. doi: 10.1200/JCO-25-01448.
    

    >> Share

    
    
39. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    

    >> Share

    
    
40. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    

    >> Share

    
    July 2025
41. WERMKE M, Gambardella V, Kuboki Y, Felip E, et al
    Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
    J Clin Oncol. 2025 Jul 24:JCO2500363. doi: 10.1200/JCO-25-00363.
    

    >> Share

    
    
42. OWEN DH, Halmos B, Puri S, Qin A, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1.
    J Clin Oncol. 2025 Jul 17:JCO2501062. doi: 10.1200/JCO-25-01062.
    

    >> Share

    
    
43. REUSS JE, Kuruvilla S, Ismaila N, Azar IH, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.
    J Clin Oncol. 2025 Jul 17:JCO2501061. doi: 10.1200/JCO-25-01061.
    

    >> Share

    
    
44. AIZER AA, Tanguturi SK, Shi DD, Catalano PJ, et al
    Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
    J Clin Oncol. 2025 Jul 11:JCO2500056. doi: 10.1200/JCO-25-00056.
    

    >> Share

    
    
45. WU Y, Bi N
    Erratum: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Jul 10:JCO2501544. doi: 10.1200/JCO-25-01544.
    

    >> Share

    
    
46. SACHER AG, Miller WH Jr, Patel MR, Paz-Ares L, et al
    Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
    J Clin Oncol. 2025 Jul 9:JCO2500040. doi: 10.1200/JCO-25-00040.
    

    >> Share

    
    June 2025
47. STEUER CE, Hayashi H, Su WC, Nishio M, et al
    Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
    J Clin Oncol. 2025 Jun 24:JCO2402744. doi: 10.1200/JCO-24-02744.
    

    >> Share

    
    
48. HE J, Tsuboi M, Weder W, Chen KN, et al
    Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2025 Jun 2:101200JCO2500883. doi: 10.1200/JCO-25-00883.
    

    >> Share

    
    
49. PIOTROWSKA Z, Passaro A, Nguyen D, Ruiter G, et al
    Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
    J Clin Oncol. 2025 Jun 1:JCO2500763. doi: 10.1200/JCO-25-00763.
    

    >> Share

    
    May 2025
50. FELIP E, Altorki N, Zhou C, Vallieres E, et al
    Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
    J Clin Oncol. 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681.
    

    >> Share

    
    
51. HUANG DD, Yang JC
    Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 May 8:JCO2500997. doi: 10.1200/JCO-25-00997.
    

    >> Share

    
    April 2025
52. DEREK DE-RUI H, Yang JC
    Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Apr 25:JCO2500625. doi: 10.1200/JCO-25-00625.
    

    >> Share

    
    
53. SCHYTTE T, Knap MM, Kristiansen C, Appelt AL, et al
    Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.
    J Clin Oncol. 2025 Apr 18:JCO2401386. doi: 10.1200/JCO-24-01386.
    

    >> Share

    
    
54. MIURA S, Tanaka H, Misumi T, Yoshioka H, et al
    Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
    J Clin Oncol. 2025 Apr 16:JCO2402007. doi: 10.1200/JCO-24-02007.
    

    >> Share

    
    
55. PEROL M, Li W, Pennell NA, Liu G, et al
    Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
    J Clin Oncol. 2025 Apr 3:JCO2500275. doi: 10.1200/JCO-25-00275.
    

    >> Share

    
    March 2025
56. THAWANI R, Bestvina CM, Vokes EE, Juloori A, et al
    Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Mar 27:JCO2402355. doi: 10.1200/JCO-24-02355.
    

    >> Share

    
    
57. WU Y, Bi N
    Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2402532. doi: 10.1200/JCO-24-02532.
    

    >> Share

    
    
58. KONG FS, Hu C, Bradley JD, Machtay M, et al
    Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2500069. doi: 10.1200/JCO-25-00069.
    

    >> Share

    
    
59. KINDLER HL, Ismaila N, Bazhenova L, Chu Q, et al
    Treatment of Pleural Mesothelioma: ASCO Guideline Update.
    J Clin Oncol. 2025;43:1006-1038.
    

    >> Share

    
    
60. SUN L, Marmarelis ME, Aggarwal C
    Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Mar 7:JCO2402624. doi: 10.1200/JCO-24-02624.
    

    >> Share

    
    February 2025
61. OWEN DH, Ismaila N, Ahluwalia A, Feldman J, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402785. doi: 10.1200/JCO-24-02785.
    

    >> Share

    
    
62. LEIGHL NB, Ismaila N, Durm G, Florez N, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3.
    J Clin Oncol. 2025 Feb 27:JCO2402786. doi: 10.1200/JCO-24-02786.
    

    >> Share

    
    
63. GAUTSCHI O, Park K, Solomon BJ, Tomasini P, et al
    Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
    J Clin Oncol. 2025 Feb 21:JCO2402076. doi: 10.1200/JCO-24-02076.
    

    >> Share

    
    
64. PIOTROWSKA Z
    Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 Feb 5:JCO2402656. doi: 10.1200/JCO-24-02656.
    

    >> Share

    
    January 2025
65. JANNE PA, Wang BC, Cho BC, Zhao J, et al
    First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
    J Clin Oncol. 2025 Jan 29:JCO2401269. doi: 10.1200/JCO-24-01269.
    

    >> Share

    
    
66. REMON J, Bortolot M, Bironzo P, Cortiula F, et al
    De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
    J Clin Oncol. 2025 Jan 21:JCO2402347. doi: 10.1200/JCO-24-02347.
    

    >> Share

    
    
67. WERR L, Bartenhagen C, Rosswog C, Cartolano M, et al
    TERT Expression and Clinical Outcome in Pulmonary Carcinoids.
    J Clin Oncol. 2025;43:214-225.
    

    >> Share

    
    
68. AWAD MM, Forde PM, Girard N, Spicer J, et al
    Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
    J Clin Oncol. 2025 Jan 8:JCO2402239. doi: 10.1200/JCO-24-02239.
    

    >> Share

    
    
69. PARK CJ, Lee ATM, Ou SI
    ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Jan 7:JCO2402514. doi: 10.1200/JCO-24-02514.
    

    >> Share

    
    
70. SANDS J, Ahn MJ, Lisberg A, Cho BC, et al
    Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
    J Clin Oncol. 2025 Jan 6:JCO2401349. doi: 10.1200/JCO-24-01349.
    

    >> Share

    
    December 2024
71. 
    Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Dec 20:JCO2402719. doi: 10.1200/JCO-24-02719.
    

    >> Share

    
    
72. LUO LY, Xue W, Qumseya A, Vasquez JC, et al
    Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    J Clin Oncol. 2024;42:4263-4270.
    

    >> Share

    
    
73. SIKKEMA BJ, Baart SJ, Paats MS, Smit EF, et al
    Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials.
    J Clin Oncol. 2024 Dec 11:JCO2401579. doi: 10.1200/JCO-24-01579.
    

    >> Share

    
    November 2024
74. KALEMKERIAN GP, Khurshid H, Ismaila N
    Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 Nov 20:JCO2402245. doi: 10.1200/JCO-24-02245.
    

    >> Share

    
    
75. NOGUCHI M, Shindo Y, Wakabayashi K, Koide Y, et al
    Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2401876. doi: 10.1200/JCO-24-01876.
    

    >> Share

    
    
76. RUSTHOVEN CG, Miao E, Boe LA, Pike LRG, et al
    Reply to: Significance of Up-Front Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Patients With Brain Metastases in the Era of New Generation Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2024 Nov 15:JCO2402129. doi: 10.1200/JCO-24-02129.
    

    >> Share

    
    
77. 
    Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Nov 12:JCO2402413. doi: 10.1200/JCO-24-02413.
    

    >> Share

    
    
78. BAZHENOVA L, Ismaila N, Abu Rous F, Alluri K, et al
    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2.
    J Clin Oncol. 2024 Nov 12:JCO2402133. doi: 10.1200/JCO-24-02133.
    

    >> Share

    
    October 2024
79. LEIGHL NB, Akamatsu H, Lim SM, Cheng Y, et al
    Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
    J Clin Oncol. 2024;42:3593-3605.
    

    >> Share

    
    
80. KENMOTSU H
    Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen?
    J Clin Oncol. 2024 Oct 11:JCO2401921. doi: 10.1200/JCO-24-01921.
    

    >> Share

    
    
81. LE X, Patel JD, Shum E, Baik C, et al
    A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
    J Clin Oncol. 2024 Oct 8:JCO2400533. doi: 10.1200/JCO.24.00533.
    

    >> Share

    
    
82. SUN H, Li M, Huang W, Zhang J, et al
    Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Tria
    J Clin Oncol. 2024 Oct 7:JCO2302075. doi: 10.1200/JCO.23.02075.
    

    >> Share

    
    
83. OWEN D, Chapman CH
    Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.
    J Clin Oncol. 2024 Oct 4:JCO2401448. doi: 10.1200/JCO-24-01448.
    

    >> Share

    
    
84. KONG FS, Hu C, Pryma DA, Duan F, et al
    Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment (18)F-Fluorodeoxyglucose Position Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung C
    J Clin Oncol. 2024 Oct 4:JCO2400022. doi: 10.1200/JCO.24.00022.
    

    >> Share

    
    
85. COOPER AJ, Riely GJ
    Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug Conjugates in Lung Cancer?
    J Clin Oncol. 2024 Oct 1:JCO2401900. doi: 10.1200/JCO-24-01900.
    

    >> Share

    
    September 2024
86. 
    Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
    J Clin Oncol. 2024 Sep 13:JCO2401883. doi: 10.1200/JCO-24-01883.
    

    >> Share

    
    
87. AHN MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al
    Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
    J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544.
    

    >> Share

    
    
88. LOVLY CM
    New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
    J Clin Oncol. 2024 Sep 4:JCO2401147. doi: 10.1200/JCO.24.01147.
    

    >> Share

    
    
89. CAMIDGE DR, Bar J, Horinouchi H, Goldman J, et al
    Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
    J Clin Oncol. 2024;42:3000-3011.
    

    >> Share

    
    August 2024
90. DOWLATI A, Hummel HD, Champiat S, Olmedo ME, et al
    Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
    J Clin Oncol. 2024 Aug 29:JCO2400553. doi: 10.1200/JCO.24.00553.
    

    >> Share

    
    
91. KETPUEAK T, Tan DSW, Popat S
    Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?
    J Clin Oncol. 2024 Aug 26:JCO2400829. doi: 10.1200/JCO.24.00829.
    

    >> Share

    
    
92. YANG JC, Lee DH, Lee JS, Fan Y, et al
    Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor?Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747.
    

    >> Share

    
    
93. GREER JA, Post KE, Chabria R, Aribindi S, et al
    Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer.
    J Clin Oncol. 2024 Aug 1:JCO2400048. doi: 10.1200/JCO.24.00048.
    

    >> Share

    
    July 2024
94. YANG JJ, Zhang Y, Wu L, Hu J, et al
    Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
    J Clin Oncol. 2024 Jul 26:JCO2302363. doi: 10.1200/JCO.23.02363.
    

    >> Share

    
    
95. PIKE LRG, Miao E, Boe LA, Patil T, et al
    Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668.
    

    >> Share

    
    
96. DALY ME, Singh N, Ismaila N
    Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Recommendation Update.
    J Clin Oncol. 2024 Jul 23:JCO2401324. doi: 10.1200/JCO-24-01324.
    

    >> Share

    
    
97. DZIADZIUSZKO R, Rzyman W
    At the Crossroads of Local and Systemic Treatment of Operable Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 23:JCO2401099. doi: 10.1200/JCO.24.01099.
    

    >> Share

    
    
98. ELKRIEF A, Montesion M, Sivakumar S, Hale C, et al
    Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jul 22:JCO2301488. doi: 10.1200/JCO.23.01488.
    

    >> Share

    
    
99. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    

    >> Share

    
    
100. BLAKELY CM, Urisman A, Gubens MA, Mulvey CK, et al
     Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
     J Clin Oncol. 2024 Jul 19:JCO2400071. doi: 10.1200/JCO.24.00071.
     

     >> Share

     
     
101. PEROL M
     TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
     J Clin Oncol. 2024 Jul 10:JCO2401043. doi: 10.1200/JCO.24.01043.
     

     >> Share

     
     June 2024
102. WALIANY S, Lin JJ
     Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer.
     J Clin Oncol. 2024 Jun 28:JCO2401062. doi: 10.1200/JCO.24.01062.
     

     >> Share

     
     
103. 
     Erratum: Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
     J Clin Oncol. 2024 Jun 17:JCO2401092. doi: 10.1200/JCO.24.01092.
     

     >> Share

     
     
104. YU Y, Miao E, Pike LRG
     Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
     J Clin Oncol. 2024;42:2107-2108.
     

     >> Share

     
     
105. PARK S, Baldry R, Jung HA, Sun JM, et al
     Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
     J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
     

     >> Share

     
     
106. PEROL M, Solomon BJ, Goto K, Park K, et al
     CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
     J Clin Oncol. 2024 Jun 3:JCO2400724. doi: 10.1200/JCO.24.00724.
     

     >> Share

     
     
107. LI W, Xiong A, Yang N, Fan H, et al
     Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
     J Clin Oncol. 2024 Jun 1:JCO2400731. doi: 10.1200/JCO.24.00731.
     

     >> Share

     
     May 2024
108. SOLOMON BJ, Liu G, Felip E, Mok TSK, et al
     Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
     J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581.
     

     >> Share

     
     
109. PAZ-ARES LG, Juan-Vidal O, Mountzios GS, Felip E, et al
     Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
     J Clin Oncol. 2024 May 31:JCO2400733. doi: 10.1200/JCO.24.00733.
     

     >> Share

     
     
110. OWEN DH, Ismaila N, Freeman-Daily J, Roof L, et al
     Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.
     J Clin Oncol. 2024 May 30:JCO2400762. doi: 10.1200/JCO.24.00762.
     

     >> Share

     
     
111. MO DC, Chen L, Wu Y, Huang JF, et al
     PD-L1 Expression and Its Prognostic Value in Different Tumor Specimens in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
     J Clin Oncol. 2024 May 16:JCO2400230. doi: 10.1200/JCO.24.00230.
     

     >> Share

     
     April 2024
112. SPIGEL DR, Dowlati A, Chen Y, Navarro A, et al
     RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
     J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110.
     

     >> Share

     
     
113. DAI W, Wang Y, Liao J, Wei X, et al
     Electronic Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial.
     J Clin Oncol. 2024 Apr 4:JCO2301854. doi: 10.1200/JCO.23.01854.
     

     >> Share

     
     March 2024
114. NEAL J, Pavlakis N, Kim SW, Goto Y, et al
     CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
     J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166.
     

     >> Share

     
     
115. POTTER AL, Xu NN, Senthil P, Srinivasan D, et al
     Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
     J Clin Oncol. 2024 Mar 27:JCO2301780. doi: 10.1200/JCO.23.01780.
     

     >> Share

     
     
116. KATHURIA H, Wiener RS
     Toward Racial Equity in Lung Cancer Screening Eligibility.
     J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351.
     

     >> Share

     
     
117. RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al
     Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.
     J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045.
     

     >> Share

     
     February 2024
118. HENICK BS, Herzberg BO, Concepcion-Crisol CP, Taylor AM, et al
     Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.
     J Clin Oncol. 2024 Feb 29:JCO2302339. doi: 10.1200/JCO.23.02339.
     

     >> Share

     
     
119. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
     Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
     J Clin Oncol. 2024 Feb 28:JCO2302746. doi: 10.1200/JCO.23.02746.
     

     >> Share

     
     
120. JAIYESIMI IA, Leighl NB, Ismaila N, Alluri K, et al
     Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
     J Clin Oncol. 2024 Feb 28:JCO2302744. doi: 10.1200/JCO.23.02744.
     

     >> Share

     
     
121. PIPER VALLILLO AJ, Viray H, Feldman J, Rangachari D, et al
     Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.
     J Clin Oncol. 2024 Feb 27:JCO2302417. doi: 10.1200/JCO.23.02417.
     

     >> Share

     
     
122. REMON J, Besse B, Aix SP, Callejo A, et al
     Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521.
     

     >> Share

     
     January 2024
123. MOK T, Nakagawa K, Park K, Ohe Y, et al
     Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
     J Clin Oncol. 2024 Jan 22:JCO2301017. doi: 10.1200/JCO.23.01017.
     

     >> Share

     
     
124. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
     Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
     

     >> Share

     
     
125. RICCIUTI B, Lamberti G, Puchala SR, Mahadevan NR, et al
     Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2024 Jan 11:JCO2300580. doi: 10.1200/JCO.23.00580.
     

     >> Share

     
     
126. FENG YN, Xiao L, Xie GY
     Atezolizumab in Advanced Squamous Cell Carcinoma of the Penis.
     J Clin Oncol. 2024;42:242-243.
     

     >> Share

     
     
127. MERIC-BERNSTAM F, Makker V, Oaknin A, Oh DY, et al
     Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
     J Clin Oncol. 2024;42:47-58.
     

     >> Share

     
     December 2023
128. 
     Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
     J Clin Oncol. 2023 Dec 19:JCO2302574. doi: 10.1200/JCO.23.02574.
     

     >> Share

     
     
129. DE VIS JB, Cmelak AJ, Osmundson EC
     Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?
     J Clin Oncol. 2023 Dec 11:JCO2302151. doi: 10.1200/JCO.23.02151.
     

     >> Share

     
     
130. LEHRER EJ, Trifiletti DM, Fadul CE, Brown PD, et al
     Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations.
     J Clin Oncol. 2023 Dec 11:JCO2301876. doi: 10.1200/JCO.23.01876.
     

     >> Share

     
     
131. 
     Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
     

     >> Share

     
     
132. JANNE PA, Planchard D, Kobayashi K, Cheng Y, et al
     CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2023 Dec 2:JCO2302219. doi: 10.1200/JCO.23.02219.
     

     >> Share

     
     
133. TAN DSW, Felip E, de Castro G, Solomon BJ, et al
     Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
     J Clin Oncol. 2023 Dec 1:JCO2300980. doi: 10.1200/JCO.23.00980.
     

     >> Share

     
     November 2023
134. UPRETY D, Remon J, Peters S
     First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
     J Clin Oncol. 2023 Nov 30:JCO2301524. doi: 10.1200/JCO.23.01524.
     

     >> Share

     
     
135. OHRI N, Jolly S, Cooper BT, Kabarriti R, et al
     Selective Personalized Radioimmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial.
     J Clin Oncol. 2023 Nov 21:JCO2300627. doi: 10.1200/JCO.23.00627.
     

     >> Share

     
     
136. RUDIN CM, Liu SV, Soo RA, Lu S, et al
     SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
     J Clin Oncol. 2023 Nov 17:JCO2301363. doi: 10.1200/JCO.23.01363.
     

     >> Share

     
     
137. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
     First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
     J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
     

     >> Share

     
     October 2023
138. PARK S, Kim TM, Han JY, Lee GW, et al
     A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).
     J Clin Oncol. 2023 Oct 20:101200JCO2301891. doi: 10.1200/JCO.23.01891.
     

     >> Share

     
     
139. HENDRIKS LEL, Remon J
     Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non-Small-Cell Lung Cancer.
     J Clin Oncol. 2023 Oct 12:JCO2301830. doi: 10.1200/JCO.23.01830.
     

     >> Share

     
     
140. KHURSHID H, Ismaila N, Bian J, Dabney R, et al
     Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
     J Clin Oncol. 2023 Oct 11:JCO2301435. doi: 10.1200/JCO.23.01435.
     

     >> Share

     
     
141. GARON EB, Lu S, Goto Y, De Marchi P, et al
     Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
     J Clin Oncol. 2023 Oct 3:JCO2300910. doi: 10.1200/JCO.23.00910.
     

     >> Share

     
     September 2023
142. 
     Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
     J Clin Oncol. 2023 Sep 13:JCO2301849. doi: 10.1200/JCO.23.01849.
     

     >> Share

     
     
143. GOTO K, Goto Y, Kubo T, Ninomiya K, et al
     Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
     J Clin Oncol. 2023 Sep 11:JCO2301361. doi: 10.1200/JCO.23.01361.
     

     >> Share

     
     
144. HOE HJ, Solomon BJ
     Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better.
     J Clin Oncol. 2023 Sep 11:JCO2301768. doi: 10.1200/JCO.23.01768.
     

     >> Share

     
     
145. YU HA, Goto Y, Hayashi H, Felip E, et al
     HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
     J Clin Oncol. 2023 Sep 10:JCO2301476. doi: 10.1200/JCO.23.01476.
     

     >> Share

     
     August 2023
146. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
     Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
     J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share